Biodesix, Inc. (NASDAQ:BDSX) Short Interest Up 499.1% in January

30 Jan 2026, 08:14 by Mitch Edgeman · The Markets Daily

Biodesix, Inc. (NASDAQ:BDSX – Get Free Report) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 483,591 shares, an increase of 499.1% from the December 31st total of 80,722 shares. Based on an average trading volume of 7,865,756 shares, the short-interest ratio is currently 0.1 days. Approximately 8.7% of the company’s stock are sold short. Approximately 8.7% of the company’s stock are sold short. Based on an average trading volume of 7,865,756 shares, the short-interest ratio is currently 0.1 days.

Insider Transactions at Biodesix

In other Biodesix news, Director Jack W. Schuler bought 82,465 shares of the business’s stock in a transaction on Thursday, January 22nd. The shares were acquired at an average cost of $10.96 per share, for a total transaction of $903,816.40. Following the purchase, the director owned 1,463,210 shares in the company, valued at approximately $16,036,781.60. This trade represents a 5.97% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders purchased 182,465 shares of company stock valued at $2,084,616 and sold 2,247 shares valued at $18,154. Company insiders own 30.10% of the company’s stock.

Institutional Investors Weigh In On Biodesix

Hedge funds have recently modified their holdings of the business. XTX Topco Ltd increased its stake in shares of Biodesix by 99.4% in the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after purchasing an additional 102,494 shares in the last quarter. Millennium Management LLC bought a new position in shares of Biodesix in the third quarter worth about $113,000. Oracle Investment Management Inc. purchased a new position in shares of Biodesix during the 3rd quarter valued at about $113,000. Finally, Aberdeen Group plc purchased a new position in shares of Biodesix during the 4th quarter valued at about $1,784,000. Institutional investors own 20.96% of the company’s stock.

Biodesix Stock Down 6.5%

Biodesix stock opened at $9.66 on Friday. Biodesix has a one year low of $3.44 and a one year high of $21.60. The stock has a fifty day moving average of $7.88 and a 200 day moving average of $7.76. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84. The stock has a market cap of $76.89 million, a PE ratio of -1.74 and a beta of 0.60.

Biodesix (NASDAQ:BDSX – Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.60) by $0.44. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%.The business had revenue of $21.77 million during the quarter, compared to the consensus estimate of $20.98 million. As a group, sell-side analysts predict that Biodesix will post -0.35 EPS for the current year.

Wall Street Analyst Weigh In

BDSX has been the topic of several recent analyst reports. Wall Street Zen raised Biodesix from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Biodesix in a research note on Monday, December 22nd. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Biodesix has an average rating of “Moderate Buy” and an average price target of $32.50.

Read Our Latest Stock Analysis on Biodesix

Biodesix Company Profile

(Get Free Report)

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.